SCM
AUPH icon

Suvretta Capital Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Suvretta Capital Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-344,755
Closed -$4.27M – 91
2022
Q1 		$4.27M Buy
+344,755
New +$5.33M 0.13% 64
2020
Q4 		– Sell
-735,500
Closed -$10.8M – 108
2020
Q3 		$10.8M Buy
735,500
+579,800
+372% +$8.4M 0.2% 51
2020
Q2 		$2.53M Buy
155,700
+74,900
+93% +$1.2M 0.05% 70
2020
Q1 		$1.17M Buy
+80,800
New +$1.43M 0.03% 46

Other funds holding AUPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Suvretta Capital Management's AUPH Position: Q2 2022 in Review

Suvretta Capital Management sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2022, closing a stake of 344,755 shares — an estimated $4.27M sold.

Suvretta Capital Management first reported a position in AUPH in Q1 2020 and held it in 4 quarters. The position peaked at $10.8M in Q3 2020. 199 funds tracked by Wall St. Rank hold AUPH as of Q2 2022.

  • Suvretta Capital Management reported no remaining Aurinia Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Suvretta Capital Management sold 344,755 Aurinia Pharmaceuticals shares in Q2 2022, an estimated $4.27M.
  • Suvretta Capital Management first reported a position in Aurinia Pharmaceuticals in Q1 2020 and held it in 4 quarters.
  • Suvretta Capital Management's Aurinia Pharmaceuticals position peaked at $10.8M in Q3 2020.
  • 199 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2022.

Based on Suvretta Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.